Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Agenus reported three-year follow-up data from its Phase 1b C-800-01 study, showing a 33% overall survival rate and 21.2-month median OS for the BOT+BAL combination in refractory MSS metastatic colorectal cancer. The results demonstrated a survival plateau beyond two years in a heavily pretreated population, with 17% of patients alive and off systemic therapy at last follow-up.
Key figures
- Drug Name
- botensilimab (BOT) plus balstilimab (BAL)
- Phase Of Trial
- Phase 1b
- Median overall survival
- 21.2 months
- Patients alive off therapy
- 21 (17%)
- Two year overall survival rate
- 41%
- Three year overall survival rate
- 33%
- Confirmed objective response rate
- 21%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.